Jiangxi Institute of Biological Products Inc

06915

Company Profile

  • Business description

    Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.

  • Contact

    No. 198 Huoju Avenue
    Jinggangshan Economic and Technological Development Zone
    Jiangxi Province
    Ji’an
    CHN

    T: +86 75533209772

    https://www.jxswzp.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    33

Stocks News & Analysis

stocks

Wide moat share expects luck to turn

A tough year for jackpots however earnings are expected to normalise.
stocks

ASX share’s growth story intact despite supply constraints

Short term supply challenges but Chinese growth story remains intact.
stocks

ASX healthcare giant rallies despite a fall in profits

Easing investor concerns and signalling a return to growth.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,269.7013.70-0.15%
CAC 408,484.4331.340.37%
DAX 4026,136.56153.520.59%
Dow JONES (US)53,277.01517.800.98%
FTSE 10010,816.5668.400.64%
HKSE26,009.46310.971.21%
NASDAQ26,180.46113.290.43%
Nikkei 22566,016.36200.43-0.30%
NZX 50 Index13,972.6652.840.38%
S&P 5007,674.3733.210.43%
S&P/ASX 2009,058.906.90-0.08%
SSE Composite Index3,905.201.480.04%

Market Movers